Lack of PTEN sequesters CHK1 and initiates genetic instability

被引:276
作者
Puc, J
Keniry, M
Li, HS
Pandita, TK
Choudhury, AD
Memeo, L
Mansukhani, M
Murty, VVVS
Gaciong, Z
Meek, SEM
Piwnica-Worms, H
Hibshoosh, H
Parsons, R [1 ]
机构
[1] Columbia Univ, Herbert Irving Canc Ctr, Inst Canc Genet, New York, NY 10032 USA
[2] Columbia Univ, Herbert Irving Canc Ctr, Dept Pathol, New York, NY 10032 USA
[3] Columbia Univ, Herbert Irving Canc Ctr, Dept Med, New York, NY 10032 USA
[4] Med Univ Warsaw, Dept Internal Dis & Hypertens, PL-02097 Warsaw, Poland
[5] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA
[6] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA
[7] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA
[8] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA
关键词
D O I
10.1016/j.ccr.2005.01.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pten(-/-) cells display a partially defective checkpoint in response to ionizing radiation (IR). The checkpoint defect was traced to the ability of AKT to phosphorylate CHK1 at serine 280, since a nonphosphorylated mutant of CHK1 (S280A) complemented the checkpoint defect and restored CDC25A degradation. CHK1 phosphorylation at serine 280 led to covalent binding of 1 to 2 molecules of ubiquitin and cytoplasmic CHKII localization. Primary breast carcinomas lacking PTEN expression and having elevated AKT phosphorylation had increased cytoplasmic CHK1 and displayed aneuploidy (p < 0.005). We conclude that loss of PTEN and subsequent activation of AKT impair CHK1 through phosphorylation, ubiquitination, and reduced nuclear localization to promote genomic instability in tumor cells.
引用
收藏
页码:193 / 204
页数:12
相关论文
共 59 条
[1]   RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development [J].
Adini, I ;
Rabinovitz, I ;
Sun, JF ;
Prendergast, GC ;
Benjamin, LE .
GENES & DEVELOPMENT, 2003, 17 (21) :2721-2732
[2]   Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten [J].
Backman, SA ;
Ghazarian, D ;
So, K ;
Sanchez, O ;
Wagner, KU ;
Hennighausen, L ;
Suzuki, A ;
Tsao, MS ;
Chapman, WB ;
Stambolic, V ;
Mak, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (06) :1725-1730
[3]   PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation [J].
Baldin, V ;
Theis-Febvre, N ;
Benne, C ;
Froment, C ;
Cazales, M ;
Burlet-Schiltz, O ;
Ducommun, B .
BIOLOGY OF THE CELL, 2003, 95 (08) :547-554
[4]   Chk1 and Chk2 kinases in checkpoint control and cancer [J].
Bartek, J ;
Lukas, J .
CANCER CELL, 2003, 3 (05) :421-429
[5]   Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome [J].
Bell, DW ;
Varley, JM ;
Szydlo, TE ;
Kang, DH ;
Wahrer, DCR ;
Shannon, KE ;
Lubratovich, M ;
Verselis, SJ ;
Isselbacher, KJ ;
Fraumeni, JF ;
Birch, JM ;
Li, FP ;
Garber, JE ;
Haber, DA .
SCIENCE, 1999, 286 (5449) :2528-2531
[6]   Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation [J].
Bernardi, R ;
Liebermann, DA ;
Hoffman, B .
ONCOGENE, 2000, 19 (20) :2447-2454
[7]   A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase [J].
Blasina, A ;
Van de Weyer, I ;
Laus, MC ;
Luyten, WHML ;
Parker, AE ;
McGowan, CH .
CURRENT BIOLOGY, 1999, 9 (01) :1-10
[8]  
Blomberg I, 1999, MOL CELL BIOL, V19, P6183
[9]   Reduced expression of PTEN correlates with breast cancer progression [J].
Bose, S ;
Crane, A ;
Hibshoosh, H ;
Mansukhani, M ;
Sandweis, L ;
Parsons, R .
HUMAN PATHOLOGY, 2002, 33 (04) :405-409
[10]   Role of the Cdc25A phosphatase in human breast cancer [J].
Cangi, MG ;
Cukor, B ;
Soung, P ;
Signoretti, S ;
Moreira, G ;
Ranashinge, M ;
Cady, B ;
Pagano, M ;
Loda, M .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (06) :753-761